

PROGRAM OVERVIEW

Continuing Education Company has been organizing its Primary Care Conference Series for over 30 years. The **30th Annual Hypertension, Diabetes, and Dyslipidemia Conference** is a three-day intensive conference to be held on **June 3 – 5, 2026** at the Hyatt Regency Savannah in Savannah, Georgia. The emphasis is on practical and useful information for clinical practice. The CME conference will educate and promote improved patient outcomes in a broad range of therapeutic areas commonly encountered in the primary care practice. This conference will address these and other issues confronting the clinician who treats challenging patients with diabetes, hypertension, and dyslipidemia. The participant will learn the most current information on these issues and will be able to apply these important clinical principles back to their everyday practice to improve the care of their patients.

Over the past several years, controversies in the appropriate level of Hemoglobin A1C, BP, and LDL-Cholesterol for outcome improvement continue to occur in Type 2 diabetes, Hypertension, and Dyslipidemia, respectively. Despite the results from the ACCORD, VADT, and ADVANCE studies suggesting the benefits of reducing macrovascular disease with a more intensive strategy for A1C reduction remains unclear, individualized A1C targets for those with newly diagnosed diabetes compared to those with long standing disease are often recommended. In addition, controversy continues to exist in cholesterol control as recent guidelines suggest that one should decide on the intensity of statin-based therapy for outcome improvement in those at risk for or with established ASCVD rather than a specific goal of LDL-cholesterol reduction. Finally, the recent SPRINT trial has suggested that lower targets for BP reduction than ever achieved before can and should be achieved in high-risk adults with hypertension.

LEARNING OBJECTIVES

As a result of this educational activity, participants should be better able to:

- Formulate an efficient and effective assessment and monitoring plan of a patient's condition as it relates to hypertension, diabetes, and dyslipidemia.
- Utilize current guidelines in the diagnosis and management of hypertension, diabetes, and dyslipidemia.
- Develop individualized interventions and treatment strategies for patients presenting with hypertension, diabetes and/or dyslipidemia that will lead to the reduction of modifiable risk factors and improved long term outcomes.

ACCREDITATION

American Academy of Family Physicians: The AAFP has reviewed the *30th Annual Hypertension, Diabetes, and Dyslipidemia Conference* and deemed it acceptable for up to 15.25 live AAFP Prescribed credits. Term of Approval is from 6/3/2026 – 6/5/2026. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMA PRA Category 1 Credits™: Continuing Education Company, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Continuing Education Company designates this live activity for a maximum of 15.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

UNLABELED USE DECLARATION

During their presentation, faculty may discuss unlabeled or investigational use which is not approved for a commercial product. Faculty members are required to disclose this information to the audience when referring to an unlabeled or investigational use.

STATEMENT OF DISCLOSURE AND INDEPENDENCE

It is the policy of Continuing Education Company (CEC) to ensure all of its accredited educational activities are designed, implemented, and evaluated in accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Criteria and Policies. In accordance with ACCME requirements, CEC has Relevant Financial Relationship Disclosure Policies that are designed to ensure that accredited educational activities are fair, balanced, independent, evidence based, and based on scientific rigor.



All individuals who are in position to influence and/or control content of a CEC accredited Continuing Medical Education (CME) activity must disclose any financial interest or other relationships they have with an ineligible company, which is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. (Relevant financial interest or other relationship includes such things as grants or research support, employee, consultant, major stockholder, member of speakers' bureau, etc.) The intent of this disclosure is to provide activity participants with information to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusions. **All relevant financial relationships have been identified, mitigated, and are listed below.**

The opinions, ideas, recommendations, and perspectives expressed in the syllabus and accompanying presentations at this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Continuing Education Company, advisory boards or consultants.

REVIEW AND PLANNING COMMITTEE DISCLOSURES

The following individuals have indicated that they have no financial relationships with an ineligible company that may impact upon this CME activity:

- Raymond E. Major, MD – Reviewer
- Su Barnwell – Planner (Continuing Education Company)
- Annie Mullins, CHCP, MBA, CMP, CPCC – Planner (Continuing Education Company) Walter Ejnes, CHCP – Reviewer & Planner (Continuing Education Company)
- Lizzie Masters, CHCP – Reviewer (Continuing Education Company)
- Beth Ryan Townsend, CHCP – Reviewer (Continuing Education Company)

FACULTY DISCLOSURES

The following individuals were responsible for developing their own content, which has been reviewed by Continuing Education Company's Medical Education Advisory Committee to ensure it is unbiased. Continuing Education Company has ensured that all relevant financial relationships that faculty may have with ineligible companies have been mitigated in advance of the CME activity. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Faculty	Disclosures	Company
Jan Basile, MD Chair/Moderator	Consultant	Anylam (Hypertension)
	Consultant	AstraZeneca
	Consultant	Blue Earth Diagnostics
	Consultant, Research Grant	Corcept
	Consultant	Eli Lilly (SURPASS-CVOT)
	Research Grant	Eli Lilly (TRIUMPH)
	Consultant	Idorsia (Hypertension)
	Consultant	Mineralys
	Consultant	Novo Nordisk (Diabetes & Obesity)
	Consultant	ReCor
	Research Grant	Sonivie – THRIVE Study
Consultant	UpToDate (Hypertension Section)	
Michael Blaha, MD	Research Grant	AHA
	Advisory Board, Research Grant	Bayer
	Advisory Board, Speaker's Bureau	Boehringer Ingelheim
	Advisory Board	Eli Lilly
	Research Grant	FDA
	Advisory Board	Idorsia
	Advisory Board	Merck
	Advisory Board	New Amsterdam
	Research Grant	NIH (National Institutes of Health)
	Advisory Board	Novartis
	Advisory Board, Research Grant, Speaker's Bureau	Novo Nordisk
Consultant	Scene Health	
Kelsey Bryant, MD	Nothing to Disclose	

Ramzi Dudum, MD	Stockholder Research Grant Advisory Board Stockholder	Centene DalCor Novartis Walmart
Brent Egan, MD	Nothing to Disclose	
Gregory Hundemer, MD	Nothing to Disclose	
Cecilia Low Wang, MD	Consultant, Independent Data Monitoring Committee	Genentech/Roche
Carol Wysham, MD	Advisory Board, Speaker's Bureau Research Grant Research Grant Advisory Board, Consultant, Research Grant, Speaker's Bureau Advisory Board, Speaker's Bureau Advisory Board, Consultant, Research Grant, Speaker's Bureau	Abbott AbbVie Bayer Pharmaceuticals Eli Lilly MannKind Novo Nordisk